Automation of Cell Culture Operations and the Deployment of CellKeeper
First written in FY2016. 15 of 37 entries say "Worsened", first in FY2021-Q1. Latest entry: FY2027-H1.
Rorze moved to the "Worse" side of this theme in 2021.
0 other companies' latest entry also says "Worsened".
- FY2027-H1WorsenedAnnual report
「In the life sciences business, net sales were ¥376 million, up 2.8% year on year, and the segment loss was ¥147 million, compared with a segment loss of ¥119 million in the same period of the previous year.」
The life sciences business recorded higher revenue, while the segment loss widened from ¥119 million in the same period of the previous year to ¥147 million. - FY2026Higher revenue, substantially lower profitAnnual report
「Net sales in the life sciences business were ¥1,201 million, up 11.8% year on year, and segment income was ¥13 million, down 89.1%.」
The Life Science business reported higher revenue, while segment profit fell to ¥13 million, representing a significant deterioration in profitability. - 2026-05-06AchievedGeneral Meetings of Shareholders
「Net sales in the life sciences business were ¥1,201 million, up 11.8% year on year, and segment income was ¥13 million, down 89.1%.」
The life sciences business generated higher revenue, with segment income of ¥13 million. - FY2026-H1WorsenedAnnual report
「Revenue from the Life Science business was ¥366 million, up 9.5% year on year, and the segment loss was ¥119 million, compared with a segment loss of ¥52 million in the same period of the previous year.」
Revenue from the Life Science business increased, while the segment loss widened from ¥52 million in the same period of the previous year to ¥119 million. - FY2025-H1MitigatedAnnual report
「Revenue from the Life Science business was ¥334 million, up 118.7% year on year, and the segment loss was ¥52 million, compared with a segment loss of ¥97 million in the same period of the previous year.」
Revenue from the Life Science business increased 118.7% year on year, and the segment loss narrowed from ¥97 million to ¥52 million. However, the business remained loss-making. - FY2025-Q1MitigatedAnnual report
「Revenue from the Life Science business was ¥152 million, up 52.1% year on year, and the segment loss was ¥40 million, compared with a segment loss of ¥62 million in the same period of the previous year.」
Revenue from the Life Science business increased 52.1% year on year, and the segment loss narrowed from ¥62 million to ¥40 million. - FY2024-Q3MitigatedAnnual report
「Revenue from the Life Science business was ¥300 million, up 21.0% year on year, and the segment loss was ¥115 million, compared with a segment loss of ¥116 million in the same period of the previous year.」
Revenue from the Life Science business increased 21.0% year on year, and the segment loss narrowed slightly from ¥116 million to ¥115 million. However, the business remained loss-making. - FY2024-Q2WorsenedAnnual report
「Revenue from the Life Science business was ¥152 million, down 17.6% year on year, and the segment loss was ¥97 million, compared with a segment loss of ¥88 million in the same period of the previous year.」
Revenue from the Life Science business decreased 17.6% year on year, and the segment loss widened from ¥88 million to ¥97 million. - FY2024-Q1MitigatedAnnual report
「Revenue from the Life Science business was ¥100 million, up 123.5% year on year, and the segment loss was ¥62 million, compared with a segment loss of ¥76 million in the same period of the previous year.」
Revenue from the Life Science business increased 123.5% year on year, and the segment loss narrowed from ¥76 million to ¥62 million. - FY2023MitigatedAnnual report
「Revenue from the Life Science business was ¥1,186 million, up 57.6% from the previous fiscal year, and the segment profit was ¥89 million, up 727.7% from the previous fiscal year.」
The Life Science business reported higher revenue and improved from a segment loss in the previous fiscal year to a segment profit of ¥89 million. - FY2023-Q3WorsenedAnnual report
「Revenue from the Life Science business was ¥248 million, down 37.1% year on year, and the segment loss was ¥116 million, compared with a segment loss of ¥42 million in the same period of the previous year.」
Revenue from the Life Science business decreased 37.1% year on year, and the segment loss widened from ¥42 million to ¥116 million. - FY2023-Q2WorsenedAnnual report
「Revenue from the Life Science business was ¥185 million, down 24.2% year on year, and the segment loss was ¥88 million, compared with a segment loss of ¥42 million in the same period of the previous year.」
Revenue from the Life Science business decreased 24.2% year on year, and the segment loss widened from ¥42 million to ¥88 million. - FY2023-Q1WorsenedAnnual report
「Revenue from the Life Science business was ¥44 million, down 48.0% year on year, and the segment loss was ¥76 million, compared with a segment loss of ¥40 million in the same period of the previous year.」
Revenue from the Life Science business decreased 48.0% year on year, and the segment loss widened from ¥40 million in the same period of the previous year to ¥76 million. - FY2022-Q3WorsenedAnnual report
「Revenue from the Life Science business was ¥395 million, down 10.8% year on year, and the segment loss was ¥42 million, compared with a segment loss of ¥17 million in the same period of the previous year.」
Revenue from the Life Science business decreased 10.8% year on year, and the segment loss widened from ¥17 million to ¥42 million. - FY2022-Q2WorsenedAnnual report
「In the Life Science business, the impact of COVID-19 continued. Revenue was ¥244 million, down 5.3% year on year, and the segment loss was ¥42 million, compared with a segment loss of ¥10 million in the same period of the previous year.」
The impact of COVID-19 continued to weigh on the Life Science business, resulting in lower revenue. The segment loss also widened from ¥10 million in the same period of the previous year to ¥42 million. - FY2022-Q1WorsenedAnnual report
「Revenue from the Life Science business was ¥86 million, up 62.3% year on year, and the segment loss was ¥40 million, compared with a segment loss of ¥34 million in the same period of the previous year.」
Revenue from the Life Science business increased, while the segment loss widened from ¥34 million in the same period of the previous year to ¥40 million. - FY2021WorsenedAnnual report
「In the Life Science business, shipments were delayed due to the impact of COVID-19. As a result, revenue was ¥686 million, down 16.1% from the previous fiscal year, and the segment loss was ¥0 million, compared with a segment profit of ¥51 million in the previous fiscal year.」
The Life Science business reported lower revenue due to shipment delays and deteriorated from a segment profit in the previous fiscal year to a loss of ¥0 million. - FY2021-Q3WorsenedAnnual report
「Revenue from the Life Science business was ¥442 million, down 25.8% year on year, and the segment loss was ¥17 million, compared with a segment profit of ¥92 million in the same period of the previous year.」
Revenue from the Life Science business decreased 25.8% year on year, and the business turned from a profit of ¥92 million in the same period of the previous year to a loss of ¥17 million. - FY2021-Q2WorsenedAnnual report
「In the Life Science business, shipments of equipment were delayed due to the impact of COVID-19. As a result, revenue was ¥258 million, down 21.0% year on year, and the segment loss was ¥10 million, compared with a segment profit of ¥63 million in the same period of the previous year.」
In the Life Science business, shipments of equipment were delayed due to COVID-19, revenue fell 21.0% year on year, and the business turned from a profit in the same period of the previous year to a segment loss of ¥10 million. - FY2021-Q1WorsenedAnnual report
「Revenue from the Life Science business was ¥53 million, down 69.2% year on year, and the segment loss was ¥34 million, compared with a segment profit of ¥33 million in the same period of the previous year.」
Revenue from the Life Science business decreased 69.2% year on year, and the business turned from a segment profit of ¥33 million in the same period of the previous year to a loss of ¥34 million. - FY2020AdvancedAnnual report
「Sales of automated cell culture equipment remained strong in Japan and overseas. As a result, revenue was ¥817 million, up 92.0% from the previous fiscal year, and the segment profit was ¥51 million, compared with a segment loss of ¥83 million in the previous fiscal year.」
Revenue from the Life Science business increased 92.0% from the previous fiscal year, and the business turned from a segment loss of ¥83 million to a profit of ¥51 million. - FY2020-Q3AdvancedAnnual report
「Revenue from the Life Science business was ¥596 million, up 118.7% year on year, and the segment profit was ¥92 million, compared with a segment loss of ¥62 million in the same period of the previous year.」
Revenue from the Life Science business increased 118.7% year on year, and the business turned from a segment loss of ¥62 million in the same period of the previous year to a segment profit of ¥92 million. - FY2020-Q2AdvancedAnnual report
「Revenue from the Life Science business was ¥327 million, up 102.7% year on year, and the segment profit was ¥63 million, compared with a segment loss of ¥43 million in the same period of the previous year.」
Revenue from the Life Science business increased 102.7% year on year, and the business turned from a segment loss of ¥43 million in the same period of the previous year to a segment profit of ¥63 million. - FY2020-Q1AdvancedAnnual report
「Revenue from the Life Science business was ¥172 million, up 43.5% year on year, and the segment profit was ¥33 million, compared with a segment loss of ¥2 million in the same period of the previous year.」
Revenue from the Life Science business increased 43.5% year on year, and the business turned from a segment loss in the same period of the previous year to a segment profit of ¥33 million. - FY2019AdvancedAnnual report
「The Life Science business actively pursued sales promotion activities, including exhibiting life science-related equipment such as incubators (cell culture equipment) used for cell culture at trade shows.」
In addition to exhibiting at trade shows and other sales promotion activities, the Company pursued market development through its Chinese joint venture. Revenue from the Life Science business was ¥425 million, up 23.0% from the previous fiscal year. The segment loss was ¥83 million. - FY2019-Q3AdvancedAnnual report
「Revenue from the Life Science business was ¥272 million, up 16.3% year on year, and the segment loss was ¥62 million, compared with a segment loss of ¥104 million in the same period of the previous year.」
Revenue from the Life Science business increased 16.3% year on year, and the segment loss narrowed from ¥104 million to ¥62 million. - FY2019-Q2RestatedAnnual report
「Revenue from the Life Science business was ¥161 million, down 14.6% year on year, and the segment loss was ¥43 million, compared with a segment loss of ¥69 million in the same period of the previous year.」
The Life Science business reported lower revenue year on year, but the segment loss narrowed from ¥69 million to ¥43 million. - FY2019-Q1Revenue decline and narrower lossAnnual report
「Revenue from the Life Science business was ¥120 million, down 14.3% year on year, and the segment loss was ¥2 million, compared with a segment loss of ¥22 million in the same period of the previous year.」
The Life Science business reported lower revenue year on year, but the segment loss narrowed from ¥22 million to ¥2 million. - FY2018AdvancedAnnual report
「As a result, revenue was ¥346 million and the segment loss was ¥74 million.」
The Life Science business sold ¥346 million of equipment for the full year, while reporting a segment loss of ¥74 million. - FY2018-Q3AdvancedAnnual report
「In addition, on 1 March 2017, the Company made its affiliate アイエス・テクノロジー・ジャパン株式会社 a wholly owned subsidiary and changed its corporate name to ローツェライフサイエンス株式会社, positioning it as the core of the Life Science business from the first-quarter consolidated accounting period. The Company actively pursued sales promotion activities, including exhibiting life science-related equipment such as incubators (cell culture equipment) used for cell culture at trade shows.」
The Company pursued sales promotion activities for life science-related equipment, including exhibiting at trade shows, and cumulative revenue increased from ¥189 million in the first two quarters to ¥234 million in the first three quarters. The segment loss was ¥104 million. - FY2018-Q2AdvancedAnnual report
「On 1 March 2017, the Company made its affiliate アイエス・テクノロジー・ジャパン株式会社 a wholly owned subsidiary and changed its corporate name to ローツェライフサイエンス株式会社, positioning it as the core of the Life Science business from the first-quarter consolidated accounting period. As a result of sales of life science-related equipment, including incubators (cell culture equipment) used for cell culture, including iPS cells, and regenerative medicine, the business reported revenue of ¥189 million and a segment loss of ¥69 million.」
Sales of life science-related equipment increased from ¥140 million in the first quarter to ¥189 million on a cumulative basis for the first two quarters. The segment loss was ¥69 million. - FY2018-Q1AdvancedAnnual report
「As a result of selling life-science-related equipment, including incubators (cell culture equipment) used for culturing cells such as iPS cells and for regenerative medicine, sales in this business amounted to ¥140 million and the segment loss was ¥22 million.」
Although the CellKeeper product name itself was not mentioned this quarter, revenue of ¥140 million was disclosed from sales of life science-related equipment, including incubators. - FY2017-Q3AdvancedAnnual report
「For bio- and genomics-related equipment, consolidated sales amounted to ¥60 million, compared with ¥5 million in the same period of the previous year, following the launch of sales of the CellKeeper incubator equipped with an automatic media exchange function.」
CellKeeper generated sales of ¥60 million in the third quarter of the current consolidated cumulative period after its launch, up from ¥16 million in the previous disclosure, indicating expanded sales results. - FY2017-Q2AdvancedAnnual report
「For bio- and genomics-related equipment, we began selling in March this year the CellKeeperⓇ incubator equipped with an automatic media exchange function, which was announced last October, and conducted sales activities. As a result, consolidated sales amounted to ¥16 million, up 223.8% year on year.」
The company began selling CellKeeper and recorded sales of ¥16 million during the current cumulative quarter through its sales activities. The product progressed from the announcement stage to commercial sales and revenue recognition. - FY2016First statedAnnual report
「We announced CellKeeper®, an incubator equipped with an automatic media exchange function, as a new product that automates media exchange, which is performed manually by researchers during cell culture.」
The company announced a new product that automates media exchange in the culture of cells such as iPS cells.